Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in enterobacter cloacae complex following exposure to cefepime

Ryan K. Shields, Alina Iovleva, Ellen G. Kline, Akito Kawai, Christi L. McElheny, Yohei Doi

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

We report 2 independent patients from whom carbapenem and ceftazidime-avibactam–resistant Enterobacter cloacae complex strains were identified. The ceftazidime-avibactam resistance was attributed to a 2–amino acid deletion in the R2 loop of AmpC β-lactamase, which concurrently caused resistance to cefepime and reduced susceptibility to cefiderocol, a novel siderophore cephalosporin.

Original languageEnglish
Pages (from-to)2713-2716
Number of pages4
JournalClinical Infectious Diseases
Volume71
Issue number10
DOIs
Publication statusPublished - 15-11-2020

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in enterobacter cloacae complex following exposure to cefepime'. Together they form a unique fingerprint.

Cite this